Is tisagenlecleucel on the market?

Tisagenlecleucel (Tisagenlecleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy, or CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was approved by the U.S. Food and Drug Administration (FDA) in August 2017 and is marketed as Kymriah.

Selivermin is an immune cell therapy that involves autologousT cells collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen. The modified T cells are infused back into the patient. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) instruct T cells to target and kill leukemia cells that express CD19 on their cell surface. In a multicenter clinical trial involving children and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), the overall response rate within three months of treatment was 83%.

A common side effect of selifermin is cytokine release syndrome(CRS). Most patients will experience serious side effects. The most common serious side effect is cytokine release syndromeDLBCL) develop serious infections.